Top

Published in:

01-03-2022 | Thrombotic Thrombocytopenic Purpura | Case Report

Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases

Authors: Julie Boudali, Benjamin Hallak, Marie Haeck, Anne-Laure Sellier-Leclerc, Marc Ulrich, Paul Coppo, Stéphanie Tellier, François Provôt

Published in: Journal of Nephrology | Issue 2/2022

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.

Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836–2846CrossRef

Joly BS, Coppo P, Veyradier A (2019) An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 12:383–395CrossRef

Coppo P, Cuker A, George JN (2019) Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost 3:26–37CrossRef

Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522CrossRef

Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346CrossRef

Bhoopalan SV et al (2019) Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura. Pediatr Blood Cancer 66:e27737CrossRef

Nagel MB, Ryder A, Lobbins M, Bhatt N (2021) Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus. Pediatr Blood Cancer 68:e28534CrossRef

Kaczmarek V et al (2019) Caplacizumab for relapsing thrombotic thrombocytopenic purpura. Pediatr Nephrol Berl Ger 34:1625–1628CrossRef

Picod A, Provôt F, Coppo P (2019) Therapeutic plasma exchange in thrombotic thrombocytopenic purpura. Presse Medicale Paris Fr 1983(48):319–327CrossRef

10.

Joly BS et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e537–e546CrossRef

11.

Joly BS, Coppo P, Veyradier A (2018) Pediatric thrombotic thrombocytopenic purpura. Eur J Haematol 101:425–434CrossRef

12.

Coppo P et al (2020) A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. https://doi.org/10.1182/blood.2020008021CrossRefPubMed

13.

Dutt T et al (2020) Real-world evidence of caplacizumab use in the management of acute TTP. Blood. https://doi.org/10.1182/blood.2020007599CrossRef

Title: Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases
Authors: Julie Boudali
Benjamin Hallak
Marie Haeck
Anne-Laure Sellier-Leclerc
Marc Ulrich
Paul Coppo
Stéphanie Tellier
François Provôt
Publication date: 01-03-2022
Publisher: Springer International Publishing
Keywords: Thrombotic Thrombocytopenic Purpura
Rituximab
Rituximab
Published in: Journal of Nephrology / Issue 2/2022
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-021-00992-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Calcium pyrophosphate deposition disease involving “the largest” Bursa in the human body

Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine?

Petrus Leo: a contribution to the art of uroscopy

Significance of regulatory T cells in children with idiopathic nephrotic syndrome

Serum sodium trajectory during AKI and mortality risk

Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case–control study (The OSMOSIS Study)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials